TY - JOUR
T1 - Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis
AU - Adams, David
AU - Gonzalez-Duarte, Alejandra
AU - O'Riordan, William D.
AU - Yang, Chih Chao
AU - Ueda, Mitsuharu
AU - Kristen, Arnt V.
AU - Tournev, Ivailo
AU - Schmidt, Hartmut H.
AU - Coelho, Teresa
AU - Berk, John L.
AU - Lin, Kon Ping
AU - Vita, Giuseppe
AU - Attarian, Shahram
AU - Planté-Bordeneuve, Violaine
AU - Mezei, Michelle M.
AU - Campistol, Josep M.
AU - Buades, Juan
AU - Brannagan, Thomas H.
AU - Kim, Byoung J.
AU - Oh, Jeeyoung
AU - Parman, Yesim
AU - Sekijima, Yoshiki
AU - Hawkins, Philip N.
AU - Solomon, Scott D.
AU - Polydefkis, Michael
AU - Dyck, Peter J.
AU - Gandhi, Pritesh J.
AU - Goyal, Sunita
AU - Chen, Jihong
AU - Strahs, Andrew L.
AU - Nochur, Saraswathy V.
AU - Sweetser, Marianne T.
AU - Garg, Pushkal P.
AU - Vaishnaw, Akshay K.
AU - Gollob, Jared A.
AU - Suhr, Ole B.
N1 - Publisher Copyright:
Copyright © 2018 Massachusetts Medical Society.
PY - 2018/7/5
Y1 - 2018/7/5
N2 - BACKGROUND Patisiran, an investigational RNA interference therapeutic agent, specifically inhibits hepatic synthesis of transthyretin. METHODS In this phase 3 trial, we randomly assigned patients with hereditary transthyretin amyloidosis with polyneuropathy, in a 2:1 ratio, to receive intravenous patisiran (0.3 mg per kilogram of body weight) or placebo once every 3 weeks. The primary end point was the change from baseline in the modified Neuropathy Impairment Score+7 (mNIS+7; range, 0 to 304, with higher scores indicating more impairment) at 18 months. Other assessments included the Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) questionnaire (range, −4 to 136, with higher scores indicating worse quality of life), 10-m walk test (with gait speed measured in meters per second), and modified body-mass index (modified BMI, defined as [weight in kilograms divided by square of height in meters]×albumin level in grams per liter; lower values indicated worse nutritional status). RESULTS A total of 225 patients underwent randomization (148 to the patisiran group and 77 to the placebo group). The mean (±SD) mNIS+7 at baseline was 80.9±41.5 in the patisiran group and 74.6±37.0 in the placebo group; the least-squares mean (±SE) change from baseline was −6.0±1.7 versus 28.0±2.6 (difference, −34.0 points; P<0.001) at 18 months. The mean (±SD) baseline Norfolk QOL-DN score was 59.6±28.2 in the patisiran group and 55.5±24.3 in the placebo group; the least-squares mean (±SE) change from baseline was −6.7±1.8 versus 14.4±2.7 (difference, −21.1 points; P<0.001) at 18 months. Patisiran also showed an effect on gait speed and modified BMI. At 18 months, the least-squares mean change from baseline in gait speed was 0.08±0.02 m per second with patisiran versus −0.24±0.04 m per second with placebo (difference, 0.31 m per second; P<0.001), and the least-squares mean change from baseline in the modified BMI was −3.7±9.6 versus −119.4±14.5 (difference, 115.7; P<0.001). Approximately 20% of the patients who received patisiran and 10% of those who received placebo had mild or moderate infusion-related reactions; the overall incidence and types of adverse events were similar in the two groups. CONCLUSIONS In this trial, patisiran improved multiple clinical manifestations of hereditary transthyretin amyloidosis.
AB - BACKGROUND Patisiran, an investigational RNA interference therapeutic agent, specifically inhibits hepatic synthesis of transthyretin. METHODS In this phase 3 trial, we randomly assigned patients with hereditary transthyretin amyloidosis with polyneuropathy, in a 2:1 ratio, to receive intravenous patisiran (0.3 mg per kilogram of body weight) or placebo once every 3 weeks. The primary end point was the change from baseline in the modified Neuropathy Impairment Score+7 (mNIS+7; range, 0 to 304, with higher scores indicating more impairment) at 18 months. Other assessments included the Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) questionnaire (range, −4 to 136, with higher scores indicating worse quality of life), 10-m walk test (with gait speed measured in meters per second), and modified body-mass index (modified BMI, defined as [weight in kilograms divided by square of height in meters]×albumin level in grams per liter; lower values indicated worse nutritional status). RESULTS A total of 225 patients underwent randomization (148 to the patisiran group and 77 to the placebo group). The mean (±SD) mNIS+7 at baseline was 80.9±41.5 in the patisiran group and 74.6±37.0 in the placebo group; the least-squares mean (±SE) change from baseline was −6.0±1.7 versus 28.0±2.6 (difference, −34.0 points; P<0.001) at 18 months. The mean (±SD) baseline Norfolk QOL-DN score was 59.6±28.2 in the patisiran group and 55.5±24.3 in the placebo group; the least-squares mean (±SE) change from baseline was −6.7±1.8 versus 14.4±2.7 (difference, −21.1 points; P<0.001) at 18 months. Patisiran also showed an effect on gait speed and modified BMI. At 18 months, the least-squares mean change from baseline in gait speed was 0.08±0.02 m per second with patisiran versus −0.24±0.04 m per second with placebo (difference, 0.31 m per second; P<0.001), and the least-squares mean change from baseline in the modified BMI was −3.7±9.6 versus −119.4±14.5 (difference, 115.7; P<0.001). Approximately 20% of the patients who received patisiran and 10% of those who received placebo had mild or moderate infusion-related reactions; the overall incidence and types of adverse events were similar in the two groups. CONCLUSIONS In this trial, patisiran improved multiple clinical manifestations of hereditary transthyretin amyloidosis.
UR - http://www.scopus.com/inward/record.url?scp=85049655756&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049655756&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa1716153
DO - 10.1056/NEJMoa1716153
M3 - Article
C2 - 29972753
AN - SCOPUS:85049655756
SN - 0028-4793
VL - 379
SP - 11
EP - 21
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 1
ER -